Description
Epoxypropionamide · CAS 5694-00-8 · C3H5NO2. UNII 6G5ELX5XYN.
Identification
| CAS Registry Number | 5694-00-8 |
|---|
| PubChem CID | 91550 |
|---|
| Molecular formula | C3H5NO2 |
|---|
| IUPAC name | oxirane-2-carboxamide |
|---|
| UNII (FDA) | 6G5ELX5XYN |
|---|
Computed Descriptors
| Molecular Weight | 87.08 |
|---|
| XLogP3 | -1.2 |
|---|
| Hydrogen Bond Donor Count | 1 |
|---|
| Hydrogen Bond Acceptor Count | 2 |
|---|
| Rotatable Bond Count | 1 |
|---|
| Exact Mass | 87.032028402 |
|---|
| Monoisotopic Mass | 87.032028402 |
|---|
| Topological Polar Surface Area | 55.6 |
|---|
| Heavy Atom Count | 6 |
|---|
| Formal Charge | 0 |
|---|
Physical description & handling notes
- When heated to decomposition it emits toxic vapors of /nitroxides/.
- When heated to decomposition, it emits toxic vapors of NOx
GHS Hazard Classification
| Reported hazard statements | H302 (100%), H315 (100%), H317 (100%), H319 (100%), H335 (100%), H350 (100%), H340, H372 |
|---|
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
Documented Uses
- Alkyl mercury compounds have been used as seed disinfectants and for fungicides. They have also been used in organic synthesis. /Mercury alkyl compounds/
- The formation of glycidamide and acrylamide adducts on the N-terminal valine of hemoglobin (Hb) is directly proportional in man and rat. Comparison of free acrylamide in plasma, valine adducts on Hb and urinary S-(2-carboxyethyl)cysteine indicate that the rate of elimination of acrylamide is at least five times lower in man than in rats. Therefore, since the integrated concentration-time ratio for glycidamide to acrylamide adducts in man (0.3) is about one-half of that for rats (0.58) at low doses, the tissue dose
- The objective of this study was to compare the metabolism of acrylamide (AM) administered orally (po), dermally, intraperitoneally (ip), or by inhalation, and to measure the hemoglobin adducts produced. Rats and mice were exposed to 2.9 ppm (1,2,3-13C) and (2,3-14C)AM for 6 hr. (2,3-14C)AM (162 mg/kg) or (1,2,3-13C)AM (13 8 mg/kg) in water was administered dermally to rats for 24 hr, and (1,2,3-13C)AM was administered ip (47 mg/kg). Urine and feces were collected for 24 hr. Urine was the major elimination route in
- The major metabolite formed via the cytochrome P450 pathway is glycidamide. Species differences in the formation of this metabolite have been observed, with acrylamide converted to glycidamide to a greater extent in the mouse than in the rat, based on urinary metabolites.
- In vivo metabolite of acrylamide in rats.
- When acrylamide was administered to rats, the conversion to glycidamide was 51% following the administration of 5 mg/kg and decreased to 13% after 100 mg/kg, based on the measurement of hemoglobin adducts. The conversion of acrylamide to glycidamide was higher following subchronic dosing as well. Acrylamide hemoglobin adduct formation was approximately 2- or 4.5-fold greater for oral (20 mg/kg/day for 15, 21, 34 or 47 days) or intraperitoneal (50 mg/kg/day for 11 days) dosing, respectively, than glycidamide adduct
Synonyms
Glycidamide; Oxirane-2-carboxamide; 5694-00-8; Oxiranecarboxamide; 2,3-Epoxypropanamide; Glycidic acid amide; 2-oxiranecarboxamide; 6G5ELX5XYN; DTXSID2031374; DTXCID0011374; (+--)-oxiranecarboxamide; RefChem:143822; 227-163-2; CCRIS 2677; UNII-6G5ELX5XYN; EINECS 227-163-2
Frequently Asked Questions
What are the CAS number and molecular formula of Epoxypropionamide?
CAS 5694-00-8; molecular formula C3H5NO2; molecular weight — g/mol.
What other names is Epoxypropionamide known by?
Glycidamide, Oxirane-2-carboxamide, 5694-00-8, Oxiranecarboxamide, 2,3-Epoxypropanamide, Glycidic acid amide.
Is Epoxypropionamide classified as hazardous?
Hazard statements reported: H302, H315, H317, H319, H335.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.
